Top

Published in:

01-11-2005

Current status of dose-dense chemotherapy for breast cancer

Author: Andrew D. Seidman

Published in: Cancer Chemotherapy and Pharmacology | Special Issue 1/2005

Abstract

In an effort to improve the effectiveness of chemotherapy for breast cancer, examination of the impact of dose intensity, dose density, and treatment duration may have as much relevance as the specific antineoplastic agents utilized. After several years of pilot feasibility studies of dose-dense chemotherapy regimens, whose delivery has been made safe and feasible by the use of hematopoietic growth factor support (in particular, filgrastim), we now have phase III data demonstrating the advantages of this approach in the adjuvant treatment of breast cancer.

Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273:542–547CrossRefPubMed

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439CrossRefPubMed

Dang CT, Moynahan ME, Dickler MN, Seidman A, Fornier M, Theodoulou M, Lake D, Hurria A, Norton L, Hudis CA (2003) Phase II study of dose-dense (DD) 5-fluorouracil, epirubicin, and cyclophosphamide followed by alternating weekly paclitaxel (P) and docetaxel (D) in high-risk node-positive (N⁺) breast cancer: Feasibility and efficacy (abstract 46). Proc Am Soc Clin Oncol 22:12A

Fisher B, Bauer M, Wickerham OL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R (1983) Relation of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52:1551–1557PubMedCrossRef

Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D’Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C (2001) Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive primary breast cancer. Clin Cancer Res 7:3934–3941PubMed

Fornier MN, Seidman AD, Lake D, D’Andrea G, Bromberg J, Robson M, van Poznak CH, Panageas K, Norton L, Hudis C (2005) Increased dose-density is feasible: a pilot study of epirubicin and cyclophosphamide followed by paclitaxel at 10–11 day intervals with filgrastim support, for women with early breast carcinoma (abstract 616). Proc Am Soc Clin Oncol 23:16S

Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983–5992CrossRefPubMed

Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) (2000) Cancer medicine, 5th edn. Williams and Wilkins, Baltimore

Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer (abstract). J Clin Oncol 4:1162–1170PubMed

10.

Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L (1999) 5-Year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 17:1118–1126PubMed

11.

Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L (1999) Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 17:93–100PubMed

12.

Jackisch C, Von Minckwitz G, Raab G, Schuette M, Blohmer JU, Hilfrich J, Gerber B, Costa S, Merkle E, Eidtmann H, Lampe D, DuBois A, Tulusan A, Caputo A, Kaufmann M (2002) Primary endpoint analysis of the Geparduo-study—preoperative chemotherapy (PCT) comparing dose-dense versus sequential adriamycin/docetaxel combination in operable breast cancer (abstract 152). Breast Cancer Res Treat 76:S50

13.

Norton L (1988) A Gompertzian model of human breast cancer growth. Cancer Res 48:7067–7071PubMed

14.

Norton L, Simon R (1986) The Norton–Simon hypothesis revisited. Cancer Treat Res 70:163–169

15.

Saez RA, McGuire WL, Clark GM (1989) Prognostic factors in breast cancer. Semin Surg Oncol 5:102–110PubMedCrossRef

16.

Skipper HE (1986) Laboratory models: the historical perspective. Cancer Treat Rep 70:3–7PubMed

17.

Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Protchard KI, Hamilton A, Piccart MJ (2003) Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with dose-intensified epirubicin and cyclophosphamide plus filgrastim in locally advanced breast cancer. An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843–850CrossRefPubMed

18.

Trudeau ME (2001) Optimizing adjuvant breast cancer chemotherapy: rationale for MA.21 study. Oncology 15:7–13PubMed

19.

Untch M, Konecny G, Ditsch N, Sorokina Y, Moebus V, Muck B, Kuhn W, Bastert G, Werner C, Thomssen D, Wallwiener U, Albert G, Bothman R, Kreignberg H, Lück J, Grosshadern K (2002) Dose-dense sequential epirubicin–paclitaxel as preoperative treatment of breast cancer: results of a randomized trial AGO study (abstract 133). Proc Am Soc Clin Oncol 21:34A

20.

Wood W, Budman D, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR (1994) Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253–1259CrossRefPubMed

Title: Current status of dose-dense chemotherapy for breast cancer
Author: Andrew D. Seidman
Publication date: 01-11-2005
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue Special Issue 1/2005
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0109-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2005

The use of aromatase inhibitors in adjuvant therapy for early breast cancer

Preface

Trastuzumab: updates and future issues

Translational studies for target-based drugs

Drug resistance in chemotherapy for breast cancer

Clinical significance of estrogen receptor β in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer